Skip to main content

Media Kit

About the remedē® System

The remedē System is a breakthrough implantable system that safely and effectively treats moderate to severe Central Sleep Apnea (CSA) in adult patients. CSA is a serious breathing disorder that disrupts the normal breathing pattern during sleep and has been shown to negatively impact quality of life and heart health.1

In a clinical study, the remedē System has been shown to improve sleep, oxygen levels and enhance overall quality of life:

  • 88% of patients had a reduction in Apnea-Hypopnea Index, an indication of CSA severity2,3
  • 78% of patients had an improvement in quality of life3
  • 90% of patients were free from serious adverse events related to the implant procedure, the device, or delivered therapy at 12 months2
Media Contact

Seamus Jackson
Vice President of Global Marketing
sjackson@zoll.com

The remedē® System Clinical Trial News Releases